Neonal Osteopenia of Prematurity: Screening and Supplementation

Neonatal osteopenia of prematurity, sometimes called metabolic bone disease of prematurity, is a condition characterised by reduced bone mineral content in infants born before 37 weeks of gestation. The third trimester is the period of greatest mineral accretion, and when birth interrupts this critical phase, the skeleton of the preterm infant often fails to achieve adequate calcium and phosphorus stores. As survival rates for very low birth weight babies continue to climb in tertiary centres across Sydney, Melbourne, Brisbane, and Perth, the long-term skeletal health of these children has become an area of intense clinical focus.

Although many cases resolve without permanent sequelae, severe osteopenia predisposes infants to fractures, dolichocephaly, and impaired linear growth during the first year of life. Modern neonatal intensive care units now treat babies as small as 500 grams, meaning clinicians must balance the demands of ventilation, fluid restriction, and prolonged parenteral nutrition against the need to build bone. Identifying affected infants early allows clinicians to intervene before demineralisation reaches a clinically dangerous threshold.

Australian guidelines, drawn from the National Health and Medical Research Council and the Australian Neonatal Society, recommend a structured approach combining biochemical surveillance with selective imaging. The international perinatal community continues to refine these protocols, with regional expertise shared through congresses hosted by the Federation of Asian and Oceania Perinatal Societies.

Understanding the Pathophysiology

The fetal skeleton accumulates roughly 80 percent of its calcium and phosphorus during the final twelve weeks of gestation. When an infant is born at 28 weeks, that mineral transfer is abruptly interrupted, leaving the neonate dependent on exogenous intake to support ongoing bone mineralisation. Insufficient substrate, combined with endocrine immaturity and the catabolic effects of critical illness, drives the characteristic fall in bone mineral content.

Phosphorus deficiency is generally considered the primary driver of osteopenia in preterm infants. Without adequate phosphate, osteoblasts cannot mineralise the organic matrix, even when calcium intake is adequate. Calcium is typically mobilised from bone to maintain serum levels, while phosphorus falls precipitously. This biochemical pattern produces a high-turnover state that, if uncorrected, culminates in radiographic rickets and clinical fractures around eight to twelve weeks of postnatal age.

Other contributors include vitamin D insufficiency, prolonged courses of loop diuretics, and the use of systemic corticosteroids for chronic lung disease. Each of these factors independently suppresses bone formation or accelerates resorption. The interplay between nutrition, pharmacology, and underlying illness means that no two infants follow an identical trajectory, and screening must be tailored to individual risk profiles.

Risk Factors in the Australian Neonatal Population

Several characteristics predict which preterm infants are most likely to develop significant osteopenia. Birth weight below 1500 grams and gestational age under 30 weeks are the most consistently reported associations. Additional contributors include prolonged exclusive parenteral nutrition beyond four weeks, exposure to antenatal or postnatal steroids, and a history of necrotising enterocolitis that delays the introduction of enteral feeds.

Australian neonatologists also pay particular attention to infants born to mothers with vitamin D deficiency, which is more prevalent among women with darker skin, those who veil for cultural reasons, and residents of southern regions such as Hobart or Adelaide during winter months. Indigenous mothers in remote communities across the Northern Territory and Western Australia likewise face an elevated risk of suboptimal vitamin D status, and their infants often require enhanced supplementation.

Social determinants further influence outcomes. Infants whose families must travel long distances from regional centres such as Darwin, Cairns, or Kalgoorlie to access tertiary NICU services may experience delays in follow-up. The Royal Flying Doctor Service plays a vital role in transporting these babies back to their communities, but continuity of bone health monitoring can be challenging once discharge occurs.

Biochemical Screening Strategies

Routine biochemical screening forms the backbone of most institutional protocols in Australia. Serum calcium, phosphorus, and alkaline phosphatase are typically measured weekly or fortnightly in infants with birth weights below 1500 grams while they remain in hospital. Urinary calcium and phosphorus excretion can also be assessed, although collection difficulties in preterms limit their utility.

Alkaline phosphatase levels above 700 to 900 IU/L, combined with serum phosphorus below 1.8 mmol/L, raise strong suspicion for evolving metabolic bone disease. Parathyroid hormone and 25-hydroxyvitamin D concentrations provide additional context and help differentiate between primary phosphorus deficiency and secondary hyperparathyroidism.

Key biochemical markers commonly monitored in Australian NICUs include:

• Serum phosphate, with target levels above 1.8 mmol/L after the second week of life
• Alkaline phosphatase, particularly the bone-specific fraction when available
• Serum calcium, although this often remains normal until late in the disease process
• 25-hydroxyvitamin D, especially in infants whose mothers had known deficiency

These biochemical data, interpreted alongside growth velocity and medication exposure, guide decisions about supplementation and imaging.

Imaging-Based Assessment Methods

When biochemical abnormalities persist or the clinical picture is unclear, imaging offers a more direct view of skeletal mineralisation. Plain radiographs of the wrist or knee can reveal overt changes such as metaphyseal cupping, fraying, and fractures. However, radiographic changes are late findings and do not allow early intervention.

Dual-energy X-ray absorptiometry (DEXA) provides a quantitative measurement of bone mineral density and is considered the reference standard where available. Australian tertiary centres with neonatal research programs, including those in Melbourne and Sydney, increasingly use DEXA in selected infants at discharge or around term-equivalent age.

Quantitative ultrasound of the tibia is an emerging radiation-free alternative that correlates reasonably well with DEXA in preterm populations. It is particularly attractive for rural follow-up clinics, where transport for DEXA scanning would otherwise impose significant burden on families. While reference values continue to be refined, serial tibial ultrasound measurements can demonstrate recovery of bone strength with appropriate nutritional rehabilitation.

Comparing Screening Modalities in Clinical Practice

This overview helps clinicians select the right tool for the right infant, balancing diagnostic yield against feasibility and family logistics.

Nutritional Supplementation Protocols

The cornerstone of managing neonatal osteopenia is optimising mineral and vitamin D intake. Human milk, while unmatched for many benefits, contains insufficient phosphorus and calcium for the needs of infants below 32 weeks gestation. Standard practice in Australian NICUs therefore involves the use of breast milk fortifiers once feeds reach around 100 mL/kg/day.

Practical supplementation considerations for clinicians and families include:

• Beginning multicomponent fortification when enteral feeds exceed 80 to 100 mL/kg/day
• Adding phosphate supplementation separately when biochemical monitoring reveals persistent hypophosphataemia despite fortification
• Providing 400 IU/day of vitamin D to all preterm infants from the first week of life, increasing to higher doses in documented deficiency
• Limiting exposure to loop diuretics and corticosteroids wherever clinically feasible, or pairing such therapies with enhanced mineral support

When oral or enteral intake is not possible, parenteral nutrition formulations in Australia typically contain calcium and phosphate at concentrations designed to mimic in utero accretion rates, although precipitation concerns often limit achievable doses. Lipid emulsions may improve calcium-phosphate delivery in modern protocols, and pharmacist input is essential when compounding bespoke solutions for the smallest infants.

After discharge, families in metropolitan areas can usually access paediatric dietitians through hospital outpatient programs, while rural families often rely on telehealth consultations coordinated by their regional general practitioner. Continued fortification of expressed breast milk or the use of post-discharge formula is frequently recommended until corrected age reaches six months or beyond, depending on growth and biochemical trajectory.

Follow-Up and Long-Term Outcomes

Most infants diagnosed with neonatal osteopenia show catch-up mineralisation within the first six to twelve months after discharge, particularly when supplementation is sustained and growth is adequate. However, emerging evidence suggests subtle reductions in peak bone mass during adolescence, particularly in those who were born extremely preterm or who had severe disease.

Developmental follow-up clinics attached to major Australian children's hospitals, such as the Royal Children's Hospital in Melbourne and Sydney Children's Hospital, monitor these children into school age. Bone health is revisited during adolescent transition, especially in those who experienced fractures in infancy or who continue to require medications such as inhaled corticosteroids.

Parental education remains a critical element of any successful prevention strategy. Mothers discharged from maternity units across Brisbane, Adelaide, and Perth are routinely counselled on the importance of vitamin D supplementation during pregnancy and lactation, and preterm infants receive clear written guidance on fortification and follow-up blood tests. Engaging families early helps bridge the gap between hospital discharge and community-based monitoring.

For clinicians seeking to deepen their knowledge of regional perinatal practice and the broader context of preterm bone health, the official FAOPS 2020 site remains a valuable repository of congress materials, abstract collections, and educational resources from the Federation of Asian and Oceania Perinatal Societies meeting held in Tokyo.